Careteq Secures ASX Listing and Charts Growth on HMR Referrals Platform
Careteq Limited (ASX:CTQ) has confirmed it will maintain its ASX listing after selling its Embedded Health Solutions subsidiary, shifting its strategic focus entirely to its HMR Referrals platform. The company reported positive operating cash flow in the March quarter and outlined plans to expand its pharmacist and GP networks while exploring AI and adjacent healthcare opportunities.
- ASX confirms no suspension following Embedded Health Solutions divestment
- Positive operating cash flow of $14k in March quarter
- Focus on expanding HMR Referrals marketplace connecting GPs and pharmacists
- Two-tranche capital raising completed to fund growth initiatives
- Plans to explore AI strategy and complementary healthcare programs
ASX Maintains Careteq Quotation After Divestment
Careteq Limited (ASX:CTQ) has secured its spot on the ASX despite the recent sale of its wholly owned subsidiary, Embedded Health Solutions (EHS). Following consultation with ASX, the company confirmed that its operational plans and financial position are sufficient to avoid suspension of its securities, with the divestment not triggering any trading halt or delisting risk.
March Quarter Marks Positive Cash Flow and Strategic Reset
The March quarter was a pivotal period for Careteq, delivering $2.192 million in customer receipts and generating a modest positive net operating cash flow of $14,000, a turnaround from the $95,000 cash outflow in the previous quarter. This improvement coincided with the completion of a two-tranche capital raising, which bolstered the company’s balance sheet and funded its transition to a new strategic focus.
HMR Referrals Becomes Core Business
With EHS sold, Careteq’s entire operational focus now rests on HMR Referrals, a Software-as-a-Service (SaaS) platform facilitating Home Medicines Reviews (HMRs) through a two-sided marketplace connecting over 500 accredited pharmacists and approximately 80 GP clinics nationally. The platform streamlines referrals under the Medicare Benefits Schedule, aiming to improve medication management outcomes.
Growth Plans Target Network Expansion and AI Integration
Careteq outlined a clear strategic roadmap for the next 12 months, centred on deepening engagement within its pharmacist and GP networks and enhancing platform integration with leading practice management systems. A key initiative is the standardisation of clinic activation to convert under-utilised government HMR schemes into increased referral volumes. Additionally, the company is exploring adjacent community pharmacy programs and potential partnerships or acquisitions to accelerate its artificial intelligence strategy and overall growth trajectory.
Capital Deployment and Funding Sufficiency
The proceeds from the EHS divestment and recent capital raise will be directed primarily towards expanding HMR Referrals, including clinic activation, pharmacist recruitment, and sector engagement. Careteq considers its current funding position adequate to support these initiatives over the next year, committing to transparent quarterly updates on progress and expenditure.
Board Confident in Long-Term Value Creation
Executive Chairman Mark Simari emphasised the board’s confidence in the company’s reset strategy, anchored in disciplined execution of the HMR Referrals growth plan and the advancement of AI capabilities. While the company remains cautious about forward-looking outcomes, the strategic focus aims to build sustainable shareholder value through targeted healthcare technology innovation.
Bottom Line?
Careteq’s pivot to a streamlined SaaS marketplace and AI exploration positions it for measured growth, but execution on network expansion and technology integration will be critical to watch.
Questions in the middle?
- How effectively can Careteq scale its HMR Referrals network to drive meaningful referral volume growth?
- What timeline and impact might the company’s AI strategy and potential acquisitions have on revenue diversification?
- Will Careteq’s funding suffice if expansion initiatives require faster or broader deployment than currently planned?
